title: Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
abstract: The hepatitis C virus (HCV) NS4B inhibitors have shown potent inhibition of HCV replication in vitro. To assess the effect of viral diversity on the susceptibility to NS4B inhibitors, genotype (GT)-specific GT1a and GT1b replicon shuttle vectors were designed and created for cloning HCV NS4B genes from clinical isolates. For the GT1b NS4B shuttle vector, the S2204I adaptive mutation was introduced in NS5A to improve replication due to the replacement of the K1846T adaptive mutation in NS4B with NS4B from the clinical isolates. In addition to the adaptive mutations, a newly identified Huh-7 cell line, Huh-7-1C, which is highly permissive for both GT1a and GT1b replication, was used to further enhance the replication levels. HCV NS4B gene from clinical isolates was amplified and inserted into the corresponding GT1a and GT1b modified lab strain chimeric replicons. GT1a and GT1b chimeric replicons expressing diverse NS4B genes from corresponding subtypes of clinical isolates replicated at highly efficient levels for phenotypic analysis. Due to natural variation in their amino acid residues in NS4B, these isolates displayed varying drug susceptibilities to an NS4B inhibitor. In mixed populations with wild-type, the sensitivity of resistance detection of NS4B resistant mutants H94R and V105M was between 20% and 80%. The chimeric shuttle vectors can be used to characterize the activity of antiviral drugs targeting NS4B from diverse natural clinical isolates and aid in the development of novel compounds against HCV NS4B.
authors.affiliation: Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, United States.
authors.forename: Sonal
authors.initials: S
authors.lastname: Rajyaguru
authors.forename: Huiling
authors.initials: H
authors.lastname: Yang
authors.forename: Ross
authors.initials: R
authors.lastname: Martin
authors.forename: Michael D
authors.initials: MD
authors.lastname: Miller
authors.forename: Hongmei
authors.initials: H
authors.lastname: Mo
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology; D002460:Cell Line; D024882:Drug Resistance, Viral; D005822:Genetic Vectors; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D006526:Hepatitis C / Q000821:virology*; D022781:Hepatocytes / Q000821:virology; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D012093:Replicon; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D014773:Virology / Q000379:methods*; D014776:Virus Cultivation / Q000379:methods; D014779:Virus Replication
chemical_list: D000998:Antiviral Agents; C080107:NS4B protein, flavivirus; D017361:Viral Nonstructural Proteins
keywords: Chimeric replicon; Clinical isolates; HCV; NS4B